Lyell Immunopharma, Inc. (LYEL)
$8.27-5.05%Close
SELLCRISIS · day 25
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $203M
- Beta
- -0.07
- P/E (TTM)
- -0.54
- Short % float
- 8.64%
- Days to cover
- 7.4
- SI change
- +6.4%
- 1W
- -8.82%
- 1M
- -30.85%
- vs SPY 1W
- -9.24%
- vs SPY 1M
- -32.91%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on LYEL?
- LOPJLB’s latest quantitative signal on Lyell Immunopharma, Inc. (LYEL) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LYEL in?
- Lyell Immunopharma, Inc. (LYEL) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Lyell Immunopharma, Inc. (LYEL) do?
- Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The companyâs lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and…